Compare Occidental Petroleum Corporation (OXY) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Occidental Petroleum Corporation vs Summit Therapeutics Inc — how do they compare? Occidental Petroleum Corporation trades at $57.7 (market cap $56.20B), while Summit Therapeutics Inc trades at $14.75 (market cap $11.34B). The key difference: Occidental Petroleum Corporation is far larger — about 5× Summit Therapeutics Inc's market cap, and Occidental Petroleum Corporation pays a 1.84% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| OXY | SMMT | |
|---|---|---|
Market Cap | $56.20B | $11.34B |
Sector | Energy | Health |
52-Week High | $66.24 | $29.32 |
52-Week Low | $38.92 | $13.05 |
Enterprise Value | $77.28B | $10.76B |
Dividend Yield | 1.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Occidental Petroleum (OXY) trades at $56.50, up 2.99% for the day, with a bullish technical signal and strong earnings beats in recent quarters. The company maintains solid profitability with a 22.42% net income margin and robust cash flow from operations of $10.53B in 2025. Recent news highlights Permian Basin growth and capital spending cuts, while analyst consensus leans bullish with a $65.38 price target.
OXY presents upside potential driven by earnings momentum and debt reduction, but faces risks from oil price volatility and declining revenue trends. The stock's elevated P/E ratio of 74.58 warrants caution, though institutional support and strategic positioning in carbon capture technology offer long-term value. Current levels near resistance at $57 require monitoring for breakout confirmation.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
